



Keeping the Outcome in Mind

Applying Best Practices for Managing HR+/HER2- EBC at High Risk of Recurrence

SATURDAY, 21 OCTOBER 2023 | 13:00–14:30 CEST

VALENCIA AUDITORIUM, HALL 10, IFEMA MADRID, MADRID, SPAIN

Medscape Oncology

MODERATOR



Sara Hurvitz, MD
 Professor of Medicine
 Head, Division of Hematology and Oncology
 Senior Vice President,
 Clinical Research Division
 Department of Medicine, UW Medicine
 Fred Hutchinson Cancer Center
 Seattle, Washington, United States

PANELISTS



Erika Hamilton, MD
 Director, Breast Cancer & Gynecologic Cancer
 Research Program
 Principal Investigator
 Sarah Cannon Cancer Institute
 Nashville, Tennessee, United States



Stephen R.D. Johnston, MA, FRCP, PhD
 Professor of Breast Cancer Medicine
 Head of Medical Oncology
 Consultant Medical Oncologist
 Head of The Breast Unit
 The Royal Marsden NHS Foundation Trust &
 The Institute of Cancer Research
 London, United Kingdom



Patrick Neven, MD, PhD
 Professor
 Universitair Ziekenhuis Leuven Breast Centre
 Leuven, Belgium

AGENDA

13:00–13:05

Welcome and Introduction

Sara Hurvitz, MD

13:05–13:20

Keeping the Outcome in Mind: The Patient With HR-Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence

Patrick Neven, MD

13:20–13:40

Latest Developments for Oral Adjuvant Therapy: Analyzing the Latest Data, Guideline Recommendations and Best Practices

Stephen R.D. Johnston, MD, PhD

13:40–14:00

Managing the Patient at Risk: Which Patients Will Benefit From Adjuvant Oral Anti-Cancer Therapies?

Sara Hurvitz, MD

Patrick Neven, MD

14:00–14:15

How to Approach Nonadherence in Practice: Clinical Pearls for the Multidisciplinary Team

Erika Hamilton, MD

14:15–14:30

Q&A Session

All Speakers

THIS CONTENT IS NOT INTENDED FOR HCPS IN SPAIN
 OR AVAILABLE FOR CREDIT FOR SPANISH HCPS.